Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Receptors, Ligands, and Catalysts on Demand using Expanded Genetic Alphabets

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: 100

    DESCRIPTION provided by applicant Technology to deliver molecules andquot on demandandquot that bind to targets or catalyze reactions of a technologistandapos s choosing would have enormous commercial value in research manufacturing and medicine Thus this has been a andquot holy grailandquot of molecular science for a half century Even today chemical theory is inadequate to support de ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. RSK3 Anchoring Disruptor Therapy for Heart Failure

    SBC: ANCHORED RSK3 INHIBITORS, LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Pathological cardiac remodeling including myocyte hypertrophy and apoptosis and myocardial interstitial fibrosis constitutes a common pathway to heart failure in disease Despite current pharmacologic therapy and other advances that attenuate remodeling mortality due to heart failure remains high New more effective therapeutic options are desperately neede ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Novel piperazine tethered thiazole compounds as antimalarials

    SBC: Smart Biomolecules, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant In spite of all the advances in molecular medicine malaria still afflicts about million people worldwide and half of the world population is at rik The disease causes nearly million deaths each year mostly children Unfortunately the prospects for control of malaria by chemotherapy have been seriously compromised by the emergence of resistance to all av ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Targeting CD137L to MC1R-Expressing Melanoma Cells and Tumors.

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    DESCRIPTION provided by applicant There are specific high affinity ligands for receptors found on many cancers that have been investigated as imaging probes and we believe that we should try to enhance immunotherapy by using these ligands to deliver immune effectors to the cancer microenvironment Melanoma is among the most immunogenic tumors known and so that disease is an excellent test bed f ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Simple Inexpensive Assay for Five Common HIV Resistance Mutations

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: NIAID

    DESCRIPTION provided by applicant Only a few inexpensive drugs can be used in the developing world for the treatment of AIDS Several of these target the HIV reverse transcriptase RT Accordingly patient therapy with these drugs often fails when the gene encoding RT undergoes mutation Thus the WHO recently reported that after months of treatment with anti RT drugs patients most often r ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Therapeutic Neutralization of the Inflammasome After Spinal Cord Injury

    SBC: INFLAMACORE LIMITED LIABILITY COMPANY            Topic: 105

    DESCRIPTION provided by applicant Spinal cord injury SCI is a complex and devastating clinical condition mediated by proinflammatory cytokines that produce neuronal loss axonal destruction and demyelination during the secondary injury cascade There are currently no proven therapies targeting posttraumatic inflammation that have been shown to have clinical value We have previously shown th ...

    STTR Phase II 2015 Department of Health and Human Services
  8. Assessing muscle health in older adults with electrical impedance myography

    SBC: Myolex Inc            Topic: NIA

    DESCRIPTION (provided by applicant): Sarcopenia, or the deterioration of muscle health with advancing age, is a major public health concern in the developed world. Some of the most important factors underlying the development of sarcopenia are age- relatedchange in muscle composition, including the replacement of muscle fibers by fat and the loss of muscle force production. Declines in muscle comp ...

    STTR Phase I 2014 Department of Health and Human Services
  9. Second generation MTI-101 analogs using a novel peptoid-peptide hybrid beta-hairp

    SBC: MODULATION THERAPEUTICS, INC.            Topic: NCI

    MTI-101 is a cyclic beta-hairpin peptide that binds CD44 with high affinity and kills multiple myeloma cell lines in vitro and blocks the growth of myeloma tumors in 2 different murine models. This interaction of MTI-101 with the surface of MM cells causesprogrammed cell necrosis, whereas all approved MM drugs cause apoptosis and so the novel mechanism of MTI-101 or MTI-like compounds makes it esp ...

    STTR Phase I 2014 Department of Health and Human Services
  10. Therapeutic Neutralization of the Inflammasome After Spinal Cord Injury

    SBC: INFLAMACORE LIMITED LIABILITY COMPANY            Topic: NINDS

    PROJECT SUMMARY Spinal cord injury (SCI) is a complex and devastating clinical condition mediated by proinflammatory cytokines that produce neuronal loss, axonal destruction, and demyelination during the secondary injury cascade. There are currently no proven therapies targeting posttraumatic inflammation that have been shown to have clinical value. We have previously shown that central nervous sy ...

    STTR Phase I 2014 Department of Health and Human Services
US Flag An Official Website of the United States Government